Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 10:49 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1225–1248 of 10,535 matching trials from the live ClinicalTrials.gov search.
Filters: Active, not recruiting Clear all
Active, not recruiting Early Phase 1 Interventional

Tolerance Through Mixed Chimerism (Sip-Tego)

NCT06972069
View directory record Official record
Conditions
Kidney Failure, Transplant Recipient (Kidney), Transplant Tolerance, Immunosuppresion, Immunosuppression After Kidney Transplantation
Interventions
Combined Kidney/Bone Marrow Transplant, Donation of Kidney / Bone Marrow, Conditioning Regimen (Rituxan, Siplizumab (or ATGAM), Cyclophosphamide, Tegoprubart)
Procedure · Drug
Lead sponsor
Tatsuo Kawai, MD, PhD
Other
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Nov 14, 2026, 10:49 PM EST
Active, not recruiting Not applicable Interventional Results available

Neuspera's Implantable Sacral Nerve Stimulation System in Patients With Symptoms of Urinary Urgency Incontinence (UUI)

NCT04232696
View directory record Official record
Conditions
Urinary Urgency Incontinence
Interventions
Neuspera Implantable Sacral Nerve Stimulation System
Device
Lead sponsor
Neuspera Medical, Inc.
Industry
Eligibility
22 Years and older
Enrollment
331 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
31
States / cities
Encinitas, California • Los Angeles, California • San Diego, California + 27 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2025 · Synced Nov 14, 2026, 10:49 PM EST
Active, not recruiting Phase 1 Interventional

WEBCAMS: Walking Exercise for Brain and Cognition in Adults With Multiple Sclerosis

NCT05755061
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-remitting Multiple Sclerosis
Interventions
GEMS Plus, GEMS
Behavioral
Lead sponsor
Kessler Foundation
Other
Eligibility
16 Years to 65 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
West Orange, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Nov 14, 2026, 10:49 PM EST
Active, not recruiting Phase 1 Interventional

Adoptive Transfer of Autologous T Cells Targeted to Prostate Specific Membrane Antigen (PSMA) for the Treatment of Castrate Metastatic Prostate Cancer (CMPC)

NCT01140373
View directory record Official record
Conditions
Prostate Cancer
Interventions
engineered autologous T cells, cyclophosphamide
Biological · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Nov 14, 2026, 10:49 PM EST
Active, not recruiting Phase 3 Interventional

Nivolumab and Ipilimumab With or Without Local Consolidation Therapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer

NCT03391869
View directory record Official record
Conditions
Lung Adenocarcinoma, Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
Interventions
Ipilimumab, Local Consolidation Therapy, Nivolumab, Quality-of-Life Assessment, Radiation Therapy, Therapeutic Conventional Surgery
Biological · Procedure · Other + 1 more
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
339 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
5
States / cities
Conroe, Texas • Houston, Texas • League City, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Nov 14, 2026, 10:49 PM EST
Active, not recruiting No phase listed Observational

Disparities Among Liver Transplant Patients

NCT05981196
View directory record Official record
Conditions
End Stage Liver DIsease
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
100 participants
Timeline
2023 – 2026
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Nov 14, 2026, 10:49 PM EST
Active, not recruiting No phase listed Observational

Ventricular Remodeling and Heart Failure After Myocardial Infarction: A Community Study

NCT02047396
View directory record Official record
Conditions
Heart Failure, Myocardial Infarction
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
1,599 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2030
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 23, 2026 · Synced Nov 14, 2026, 10:49 PM EST
Active, not recruiting Early Phase 1 Interventional

Zr89 + PET Companion Trial

NCT05279027
View directory record Official record
Conditions
Melanoma (Skin)
Interventions
Zirconium Zr 89 Crefmirlimab Berdoxa
Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Nov 14, 2026, 10:49 PM EST
Active, not recruiting Early Phase 1 Interventional

Daily Aspirin Treatment After Preeclampsia

NCT06168461
View directory record Official record
Conditions
Preeclampsia
Interventions
Aspirin, Placebo
Drug
Lead sponsor
Anna Stanhewicz, PhD
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Oct 28, 2026 · Synced Nov 14, 2026, 10:49 PM EST
Active, not recruiting Not applicable Interventional

Reduction in Number of Botox Injections for Urgency Urinary Incontinence

NCT04731961
View directory record Official record
Conditions
Urgency Urinary Incontinence
Interventions
Standard of care (15 Botox injections), Experimental Arm (5 Botox injections)
Procedure
Lead sponsor
University of Virginia
Other
Eligibility
21 Years and older · Female only
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Nov 14, 2026, 10:49 PM EST
Active, not recruiting No phase listed Observational

Sleep and Physical Activity in Patient and Caregiver Dyads Following Allogeneic Hematopoietic Cell Transplantation

NCT07140770
View directory record Official record
Conditions
Physical Activity, Sleep, Allogenic Hematopoietic Cell Transplant
Interventions
Fitbit, Questionnaire
Device · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Nov 14, 2026, 10:49 PM EST
Active, not recruiting Phase 2 Interventional

Naxitamab for High-Risk Neuroblastoma Patients With Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone and/or Bone Marrow

NCT03363373
View directory record Official record
Conditions
Neuroblastoma
Interventions
GM-CSF + Naxitamab
Biological
Lead sponsor
Y-mAbs Therapeutics
Industry
Eligibility
1 Year and older
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2028
U.S. locations
2
States / cities
Indianapolis, Indiana • New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Nov 14, 2026, 10:49 PM EST
Active, not recruiting No phase listed Observational

Post Market Clinical Follow-Up Study in Patients Treated With the On-X Ascending Aortic Prosthesis (AAP)

NCT05082454
View directory record Official record
Conditions
Aortic Valve Disease
Interventions
Open repair
Device
Lead sponsor
JOTEC GmbH
Industry
Eligibility
18 Years and older
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
3
States / cities
Danville, Pennsylvania • Houston, Texas • Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 5, 2025 · Synced Nov 14, 2026, 10:49 PM EST
Active, not recruiting Phase 2 Interventional

Daratumumab, Bortezomib, and Dexamethasone Followed by Daratumumab, Ixazomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

NCT03763162
View directory record Official record
Conditions
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
Interventions
Bortezomib, Daratumumab, Dexamethasone, Ixazomib, Quality-of-Life Assessment
Drug · Biological · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Nov 14, 2026, 10:49 PM EST
Active, not recruiting Phase 2 Interventional Results available

A Study to Investigate Efficacy and Safety With Oral AZD9833 Compared With Intramuscular Fulvestrant in Post-menopausal Women at Least 18 Years of Age With Advanced ER-positive HER2 Negative Breast Cancer

NCT04214288
View directory record Official record
Conditions
Advanced ER-Positive HER2-Negative Breast Cancer
Interventions
AZD9833, Fulvestrant
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years · Female only
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
9
States / cities
Birmingham, Alabama • Long Beach, California • Fort Myers, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Nov 14, 2026, 10:49 PM EST
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Comprehensive Lifestyle Change To Prevent Breast Cancer

NCT03448003
View directory record Official record
Conditions
Premenopausal
Interventions
Cancer Prevention, Questionnaire Administration
Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Nov 14, 2026, 10:49 PM EST
Active, not recruiting Phase 3 Interventional

Study Comparing Investigational Drug HBI-8000 + Nivolumab vs. Placebo + Nivolumab in Patients With Advanced Melanoma

NCT04674683
View directory record Official record
Conditions
Unresectable or Metastatic Melanoma, Progressive Brain Metastasis
Interventions
HBI-8000 in combination with nivolumab, Placebo in combination with nivolumab
Drug
Lead sponsor
HUYABIO International, LLC.
Industry
Eligibility
12 Years and older
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
31
States / cities
Bakersfield, California • La Jolla, California • Pasadena, California + 28 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2025 · Synced Nov 14, 2026, 10:49 PM EST
Active, not recruiting Phase 3 Interventional

Escitalopram for Agitation in Alzheimer's Disease

NCT03108846
View directory record Official record
Conditions
Dementia
Interventions
Escitalopram, Placebo
Drug
Lead sponsor
JHSPH Center for Clinical Trials
Other
Eligibility
18 Years to 109 Years
Enrollment
187 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
22
States / cities
Sun City, Arizona • Little Rock, Arkansas • Los Angeles, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jan 31, 2025 · Synced Nov 14, 2026, 10:49 PM EST
Active, not recruiting Phase 2 Interventional Results available

Paclitaxel With or Without Cixutumumab as Second-Line Therapy in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer

NCT01142388
View directory record Official record
Conditions
Metastatic Esophageal Adenocarcinoma, Metastatic Esophageal Squamous Cell Carcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Recurrent Esophageal Adenocarcinoma, Recurrent Esophageal Carcinoma, Recurrent Esophageal Squamous Cell Carcinoma, Recurrent Gastroesophageal Junction Adenocarcinoma, Stage IV Esophageal Cancer AJCC v7
Interventions
Cixutumumab, Laboratory Biomarker Analysis, Paclitaxel, Pharmacological Study
Biological · Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2027
U.S. locations
232
States / cities
Scottsdale, Arizona • Palo Alto, California • Aurora, Colorado + 173 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2026 · Synced Nov 14, 2026, 10:49 PM EST
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

Depth of Botulinum Neurotoxin Injection for Treatment of Glabellar Lines

NCT05766683
View directory record Official record
Conditions
Glabellar Frown Lines
Interventions
onabotulinumtoxinA at a depth of 2mm, onabotulinumtoxinA at a depth of 4mm
Drug
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Nov 14, 2026, 10:49 PM EST
Active, not recruiting Not applicable Interventional

Optimization of a mHealth Physical Activity Promotion Intervention With Mindful Awareness for AYAO (OPT2MOVE)

NCT05375162
View directory record Official record
Conditions
Cancer
Interventions
Core Intervention, E-Coach, General Mindfulness Training, MVPA-Specific Mindfulness Training, Buddy
Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 39 Years
Enrollment
304 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
2
States / cities
Chicago, Illinois • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Nov 14, 2026, 10:49 PM EST
Active, not recruiting Phase 2 Interventional

A Study to Assess Safety and Effectiveness of Elafibranor in Adult Participants With Primary Sclerosing Cholangitis.

NCT05627362
View directory record Official record
Conditions
Primary Sclerosing Cholangitis
Interventions
Elafibranor 80 mg, Elafibranor 120 mg, Placebo Matched to Elafibranor 80 mg, Placebo Matched to Elafibranor 120 mg
Drug
Lead sponsor
Ipsen
Industry
Eligibility
18 Years to 75 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2031
U.S. locations
30
States / cities
Lancaster, California • Los Angeles, California • Sacramento, California + 26 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Nov 14, 2026, 10:49 PM EST
Active, not recruiting Not applicable Interventional

Targeted Plasticity Therapy for Posttraumatic Stress Disorder

NCT04064762
View directory record Official record
Conditions
Post Traumatic Stress Disorder
Interventions
Paired Vagus Nerve Stimulation
Device
Lead sponsor
Baylor Research Institute
Other
Eligibility
18 Years to 64 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 5, 2023 · Synced Nov 14, 2026, 10:49 PM EST
Active, not recruiting Not applicable Interventional

Improving Transition Care for Adolescents and Young Adults With Type 1 Diabetes

NCT05639088
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Transition preparation program, Educational materials
Behavioral · Other
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
16 Years and older
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 7, 2026 · Synced Nov 14, 2026, 10:49 PM EST